再次冠状动脉手术伴或不伴体外循环的早期结局与10年生存:倾向性评分匹配分析
本研究从注册数据库纳入349例再次冠状动脉手术患者,比较再次体外循环下冠状动脉旁路移植术(redo-CABG,206例)与再次非体外循环冠状动脉旁路移植术(redo-OPCAB,143例)的院内结局和10年生存。倾向性评分匹配分析显示,对于初次为单纯冠状动脉手术的患者,redo-OPCAB的复合终点和主动脉内球囊反搏使用率更低,10年生存率相似。
要点
- redo-OPCAB在匹配分析B中复合终点低于redo-CABG(8% vs 19%,P=0.04)。
- 匹配分析B中redo-OPCAB的IABP使用率显著更低(2% vs 11%,P=0.02)。
- 各分析中redo-OPCAB与redo-CABG的10年生存率均相似。
核心结论
- 再次非体外循环冠状动脉手术可行、安全有效,与再次体外循环手术相比院内结局更优且10年生存相似。
研究设计与样本
- 回顾性注册数据库研究,共纳入349例再次冠状动脉手术患者,其中redo-OPCAB 143例(40.97%),redo-CABG 206例。
- 进行倾向性评分匹配分析:匹配分析A比较111例redo-OPCAB与111例redo-CABG(初次手术为任何类型心脏手术),匹配分析B比较84例redo-OPCAB与84例redo-CABG(初次手术为单纯冠状动脉手术)。
主要发现
- 未匹配分析中,redo-CABG的IABP使用率高于redo-OPCAB(10% vs 3%,P=0.01),复合终点发生率为25% vs 16%(P=0.06),10年生存率相似(67.2% vs 68.5%,log-rank P=0.78)。
- 匹配分析A中,redo-OPCAB与redo-CABG的复合终点发生率(15% vs 21%,P=0.25)和10年生存率(65.1% vs 60.8%,log-rank P=0.5)相似。
- 匹配分析B中,redo-OPCAB的复合终点发生率更低(8% vs 19%,P=0.04),院内死亡率有降低趋势(0% vs 5%,P=0.13),IABP使用率低4.5倍(2% vs 11%,P=0.02),10年生存率相似(71.6% vs 71.7%,log-rank P=0.61)。
临床怎么用
- 对于再次冠状动脉手术患者,尤其是初次为单纯冠状动脉手术者,redo-OPCAB可考虑作为降低院内并发症的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the in-hospital health outcome and 10-year survival in patients undergoing redo coronary surgery with (redo-CABG) or without (redo-OPCAB) cardiopulmonary bypass. METHODS: A total of 349 redo coronary surgery patients were identified from our registry. Of these, 143 redo-OPCAB patients (40.97%) were compared with 206 redo-CABG patients. To minimize the bias, we also conducted propensity score matching. In Matched Analysis A, 111 redo-OPCAB patients with any type of primary cardiac operation were compared with 111 redo-CABG cases. In Matched Analysis B, 84 redo-OPCAB patients with isolated coronary surgery as their primary operation were compared with 84 redo-CABG patients. We assessed for all 3 analyses a composite of in-hospital mortality, acute kidney injury, stroke and severe low cardiac output requiring intra-aortic balloon pump. In addition, we assessed 1-, 5-, and 10-year survival. RESULTS: In the unmatched analysis, redo-CABG was associated with higher usage of intra-aortic balloon pump (10 vs 3%, P = 0.01) and composite compared with redo-OPCAB (25 vs 16%, P = 0.06) and similar 10-year survival (67.2 vs 68.5%, log-rank test: P = 0.78). Matched Analysis A showed similar rates of composite (15 vs 21%, P = 0.25) and 10-year survival (65.1 vs 60.8%, log-rank test: P = 0.5). Matched Analysis B showed reduction of the composite (19 vs 8%, P = 0.04), less in-hospital mortality (5 vs 0%, P = 0.13), 4.5 times less need for intra-aortic balloon pump (2 vs 11%, P = 0.02) favouring redo-OPCAB and a similar 10-year survival (71.6 vs 71.7%, log-rank test: P = 0.61). CONCLUSIONS: Redo-OPCAB surgery is feasible, safe and effective with improved in-hospital outcome and similar 10-year survival compared to redo-CABG.
引用
- Bruno VD, Zakkar M, Rapetto F, et al. Early health outcome and 10-year survival in patients undergoing redo coronary surgery with or without cardiopulmonary bypass: a propensity score-matched analysis. Eur J Cardiothorac Surg. 2017. PMID: 28505298. doi:10.1093/ejcts/ezx137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。